Sigachi Industries Ltd., India’s largest producer of Microcrystalline Cellulose (MCC), continues to set new benchmarks in global pharmaceutical excipients while strategically expanding into Active Pharmaceutical Ingredients (APIs) and specialty chemicals. With robust financial growth, a diversified portfolio, and an expanding global footprint, Sigachi is now powering ahead as a vertically integrated pharmaceutical player.
Sigachi has received Terms of Reference (ToR) approval from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for a cutting-edge Bulk Drugs and Specialty Chemicals facility in Orvakal, Kurnool District.
Spread over 25.09 acres in Guttapadu-Orvakal node, the development starts on August 1, 2025, post EC process initiation from July 15, 2025. It will bolster Sigachi’s API pipeline for regulated and semi-regulated markets, and enable faster commercialisation, seamless tech transfers, and greater proximity to regulatory jurisdictions.
A new API & Analytical R&D Centre in Hyderabad, launching in Q1 FY26, will centralise formulation research, data science, and excipient compatibility modelling.
Sigachi’s next frontier includes launch of Croscarmellose Sodium (CCS) in 18 months; co-processed MCCs like HiCel SMCC and HiCel MCG 591/611; and entry into 3D printed pharma and nutraceuticals.
